Navigation Links
IDEV Announces Results from Revascularization with Supera on Real World Patients (RESTORE) Study, Demonstrating Positive Clinical Outcomes in Significantly Diseased Patients with Long Lesions

WEBSTER, Texas, Jan. 31, 2013 /PRNewswire/ -- IDEV Technologies, Inc. today announced results from a new study by physicians from Tucson, Arizona, which were reported at last week's LINC meeting in Leipzig, Germany.  The data matched previously reported results with the Supera® Stent in other studies, but in a group of patients with more advanced peripheral disease.

One hundred forty-seven patients from Tucson were included in the analysis.  Long lesions were studied, with the mean lesion length of their superficial femoral artery (SFA) and popliteal artery disease of 18.4 cm, which was treated by an average stent length of 19.7 cm.  The study included patients with TASC II C & D disease (28 and 33% respectively).  In addition, 35% of the patients had tissue loss and were accounted for via Rutherford Becker 5 & 6 classification, and 53% of all patients had chronic total occlusions (CTO).  The overall primary patency rate, measured by duplex ultrasound, at one year follow-up was 88%.  Zero fractures were found within a subgroup analysis of 47 patients which received follow-up x-ray evaluation.

"Our experience included patients with a significant burden of disease," commented John Pacanowski , MD, Chief of Vascular Surgery, Tucson Medical Center. Based on the broad in-depth overall volume of data for Supera, combined with the results from our study, we believe Supera could become the stent of choice for long and calcified lesions and the primary device for highly diseased patients.  Dr. Pacanowski also noted the vascular mimetic stent (VMS) design of Supera may better serve these type of anatomy, which are characterized by a location and disease state that are subject to extreme mechanical stresses.

"We are pleased to see impressive results like these in this type of challenging patient cohort," confirmed Chris Owens , President and CEO of IDEV Technologies.  "It is encouraging that physicians are continuing to reproduce positive results such as those reported earlier in European studies, even when Supera is utilized across a broad range of disease states, operators, various studies and clinical sites."

About the Supera StentThe Supera stent is engineered with proprietary interwoven wire technology that mimics vascular anatomy.  It is currently indicated in the U.S. for the palliative treatment of biliary strictures produced by malignant neoplasms and in multiple other countries for the treatment of biliary strictures produced by malignant neoplasms and for peripheral vascular use following failed percutaneous transluminal angioplasty (PTA).

About IDEV Technologies, Inc.IDEV is a developer of endovascular technologies designed to protect and restore anatomical function. The company is focused on redefining the endovascular treatment paradigm by providing physicians and patients with a new standard of technologies that deliver clinical excellence. For more information, please visit

Trent Reutiman Global Vice President of Commercial OperationsIDEV Technologies, Incorporated(281) 525-2000

SOURCE IDEV Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
(Date:12/1/2015)... , Dec. 1, 2015 Breg, ... and services, announced today that it has been awarded ... organization. Members served by Novation will have access to ... sports bracing products and soft goods dedicated to advancing ... --> The aging U.S. population, rising prevalence of ...
(Date:12/1/2015)... , Dec. 1, 2015 Building on ... Johnson & Johnson (NYSE: JNJ ) today ... Pharmaceutical Companies to significantly reduce the burden of ... up 74 percent of new HIV infections among ... World AIDS Day, these new initiatives include collaborations ...
(Date:12/1/2015)... YORK , Dec. 1, 2015 Relmada Therapeutics, ... the treatment of chronic pain, announced today that the company ... will be held December 1-3 at the Luxe Sunset Boulevard ... Sergio Traversa , CEO of Relmada Therapeutics, will present on ... Eastern Time). . Please register at least ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Speech ... who believe that with innovative technologies and under the right circumstances, these practices ... the benefit of a dual-approach to his or her therapeutic sessions, as well ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... the 1980s we have seen vast improvements in scientific research and discoveries, leading ... strides, providing increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s cross-platform ...
(Date:12/1/2015)... ... December 01, 2015 , ... The ... been lifted as IMAGE Information Systems launches MED-TAB™ -- the world’s first portable ... Meeting from November 29 to December 4, 2015. , MED-TAB is expected ...
(Date:12/1/2015)... ... December 01, 2015 , ... For many X-rays taken at ... accurate interpretation by the radiologist. The marking utensils are so small, however, they ... found a way to alleviate this problem. , He developed the patent-pending MARK ...
(Date:12/1/2015)... ... December 01, 2015 , ... SAN FRANCISCO, Calif. ... that the organization has awarded Education and Developmental Therapies (EDT), an Applied Behavior ... award celebrates exceptional special needs providers that excel in synthesizing the areas of ...
Breaking Medicine News(10 mins):